Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Open Access
- 16 October 2023
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 16 (1) , 1166-1171
Abstract
Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (177Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of 177Lu-DOTATATE therapy, targeted alpha-particle therapy (TAT) may be a possible treatment option. Here, we present a patient with cancer of unknown primary NET G2 later G3. The patient was referred to our hospital with urosepsis due to a second-degree urinary retention. After stent insertion, a contrast-enhanced computed tomography revealed a huge pelvic tumor without metastases. Initially, the patient had undergone surgical treatment. Later the patient developed liver metastasis and was treated by 177Lu-DOTATATE therapy and four lines of systemic therapy. A disease progression was observed and with the knowledge of a germline BRCA1 mutation, the patient was treated with TAT (Actinium-225 [225Ac]-DOTATATE) combined with olaparib. The patient achieved a significant treatment response for 12 months indicating that a combination therapy with an alpha emitter and olaparib demands further investigations in clinical trials.Keywords
This publication has 18 references indexed in Scilit:
- Targeted alpha-particle therapy: imaging, dosimetry, and radiation protectionAnnals of the ICRP, 2018
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose FindingJournal of Nuclear Medicine, 2017
- The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic CategoriesNeuroendocrinology, 2016
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary SiteNeuroendocrinology, 2016
- Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor OlaparibTheranostics, 2016
- Targeting the DNA Damage Response in CancerMolecular Cell, 2015
- Genetic predisposition to pancreatic cancerWorld Journal of Gastroenterology, 2014
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC studyAnnals of Oncology, 2012
- GermlineBRCAMutations Denote a Clinicopathologic Subset of Prostate CancerClinical Cancer Research, 2010
- BRCA1 and BRCA2 and the genetics of breast and ovarian cancerHuman Molecular Genetics, 2001